Project Grant R01CA285576
Award Date
9/1/24
Completion Date
8/31/29
Dollars Obligated
$599K
Federal Agency
National Cancer Institute
Federal Grant Program
93.396
Assistance Type
Project Grant
Place of Performance
Chicago, IL 60607, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA Program 93.396 - Cancer Biology Research) totaling $2,397,277 will support research at the Sanford Burnham Prebys Medical Discovery Institute to investigate the role of metabolic stress and hypernutrition in the progression from non-alcoholic steatohepatitis (NASH) to hepatocellular carcinoma (HCC). The research will focus on understanding how interactions between cellular signaling pathways (NRF2, ATF6) and mitochondrial...
This Project Grant award, titled "EXPLOITING THERAPEUTIC VULNERABILITIES IN HEPATOCELLULAR CARCINOMA (ELEVATE)", is funded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research). The $2,678,459 award aims to advance the understanding of molecular mechanisms regulating non-alcoholic steatohepatitis (NASH)-associated hepatocellular carcinoma (HCC) and develop novel combinatorial treatment approaches. The award supports four research projects, an administrative core, a...
The National Cancer Institute (NCI) awarded a $232,515 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to Loyola University of Chicago's Health Sciences Campus. The grant, awarded on September 27, 2024, will fund research to define the molecular mechanisms by which the protein Focal Adhesion Kinase (FAK) promotes the development of hepatocellular carcinoma (HCC), a deadly form of liver cancer. The research will also investigate whether levels of the secreted protein...
This $483,591.00 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research at the University of California, Davis to develop novel biologic RNA molecules to modulate liver cancer (hepatocellular carcinoma) metabolism. The key research objectives are to: 1) design, clone, express, and purify a focused group of humanized biologic RNA molecules to inhibit liver cancer cell viability; 2) delineate the mechanisms by which these biologic RNAs...
This $127,952 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) will support research at George Washington University to study the role of the enzyme HDAC11 in liver cancer progression. The research has two main aims: 1) to determine if HDAC11-mediated modifications to the splicing factor SF3B2 impact alternative mRNA splicing in liver cancer cells, and 2) to evaluate the potential of HDAC11-specific inhibitors as a new liver cancer treatment...
The National Cancer Institute (CFDA 93.396 - Cancer Biology Research) awarded Loyola University of Chicago a $461,844 project grant titled "Hyperpolarized 13C Metabolic Imaging of Tumorigenesis in the Liver". The objective is to use novel hyperpolarized 13C probes to image glycolysis, a critical pathway in hepatocellular carcinoma (HCC) development, and establish in vivo imaging biomarkers to assess altered liver metabolism during HCC progression. The project aims to synthesize a...
This Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) is supporting research to develop novel inhibitors of the CYP8B1 protein, which plays a key role in the development of obesity-associated hepatocellular carcinoma (HCC). The $213,284 award to the Beckman Research Institute of the City of Hope will fund two aims: 1) Determining the role of CYP8B1 in obesity-associated HCC using mouse models, and 2) Performing chemical modifications and...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Cedars-Sinai Medical Center will investigate the molecular mechanisms by which metabolic dysfunction-associated steatotic liver disease (MASLD) promotes liver metastasis in gastrointestinal cancers. The $646,739 award, effective from April 1, 2025 to March 31, 2030, will focus on the roles of hepatic stellate cells (HSCs) - both intra-tumoral and extra-tumoral - and the effect of...
This $1,373,418 federal Project Grant award, provided by the National Cancer Institute (CFDA 93.396 Cancer Biology Research program), supports research into the role of the NRF2 oncogene in the metastatic spread of high-risk hepatoblastoma (HB), the most common pediatric liver cancer. The Baylor College of Medicine, the prime awardee, aims to thoroughly characterize the molecular mechanisms by which NRF2 drives HB cell dissemination, invasion, and metastasis. The 5-year project involves in vitro...
The federal Project Grant award R01DK140159, funded by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), aims to investigate the potential of a novel adipokine in resolving non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) in animal models. The $469,235 award, with a start date of September 1, 2024, and an ultimate completion date of June 30,...